1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
246.73 USD   +0.48%
06/15Amgen Inc. Reaffirms Revenue Guidance for the Year 2022
CI
06/15TRANSCRIPT : Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 10:40 AM
CI
06/10Amgen announces webcast of goldman sachs 43rd annual healthcare conference
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE

05/09/2022 | 09:21am EDT

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) will present at the 2022 Bank of America Healthcare Conference at 12:20 p.m. ET on Wednesday, May 11, 2022. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World's Best Workplaces by Fortune and Great Place to Work and one of the 100 most sustainable companies in the world by Barron's.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Contact:

Amgen

Thousand Oaks

Media

Megan Fox

T: 805-447-1423

Jessica Akopyan

T: 805-447-0974

Investors

Arvind Sood

T: 805-447-1060

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about AMGEN INC.
06/15Amgen Inc. Reaffirms Revenue Guidance for the Year 2022
CI
06/15TRANSCRIPT : Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference..
CI
06/10Amgen announces webcast of goldman sachs 43rd annual healthcare conference
PR
06/08BEHIND ONE BIOTECH'S WATER CONSERVAT : Saving Every Drop
PU
06/08TRANSCRIPT : Amgen Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-20..
CI
06/07Amgen - FDA APPROVES RIABNI (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN (RITUXIMAB), FOR ..
AQ
06/06NEW BPCIA COMPLAINT : Genentech Files Suit Against Tanvex Regarding Its Proposed Herceptin..
AQ
06/06Amgen Says FDA Approves Riabni to Treat Rheumatoid Arthritis
MT
06/06FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ..
PR
06/06Amgen Inc. Announces U.S. Food and Drug Administration Approves RIABNI
CI
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 214 M - -
Net income 2022 6 802 M - -
Net Debt 2022 26 905 M - -
P/E ratio 2022 19,5x
Yield 2022 3,08%
Capitalization 131 B 131 B -
EV / Sales 2022 6,03x
EV / Sales 2023 5,73x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 246,73 $
Average target price 246,51 $
Spread / Average Target -0,09%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.9.67%131 173
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782